PRIMARY STUDY

β‐caryophyllene and β‐caryophyllene oxide—natural compounds of anticancer and analgesic properties.

Key Findings:  Treatment with this compound reduces the exprThe selective activation of CB2 may be considered a novel strategy in pain treatment, devoid of psychoactive side effects associated with CB1 stimulation. Thus, BCP as selective CB2 activator may be taken into account as potential natural analgesic drug. Moreover, due to the fact that chronic pain is often an element of cancer disease, the double activity of BCP, anticancer and analgesic, as well as its beneficial influence on the efficacy of classical chemotherapeutics, is particularly valuable in oncology.

Type of Study:  Meta-analysis

Study Result:  Positive

Study Location(s):  Poland

Year of Pub:  2016


Cannabinoids Studied: 

Phytocannabinoid Source:  Not Applicable

Terpenes Studied:  ß-Caryophyllene, Humulene

Receptors Studied:  CB1, CB2, GPCR